Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia | Aplastic Anemia & MDS International Foundation
Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia

Clinical Trial: NCT02224872

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 
  • Procedure: Bone marrow transplant
    Day 0
  • Drug: Thymoglobulin
    0.5 mg/kg IV on Day -9 2 mg/kg IV on Days -8, -7
  • Drug: Fludarabine
    30 mg/M2 IV on days -6 to -2
  • Drug: Cyclophosphamide
    14.5 mg/kg IV on days -6, -5, 3, 4

    Other Name: CTX
  • Radiation: TBI
    200 cGy on day -1
  • Drug: Mesna
    40 mg/kg IV on days 3, 4
  • Drug: Tacrolimus
    For patients 18 years or older, tacrolimus will be given per institutional standards; may be increased or later changed to a PO BID schedule. Treatment to continue until Day 365 or longer if GVHD present
  • Drug: Mycophenolic acid mofetil
    15 mg/kg PO/IV TID beginning on day 5 through day 35

    Other Name: MMF
Status: 
Recruiting
Study Date: 
Fri, 08/01/2014 to Wed, 08/01/2018
Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
Intervention: 
Procedure: Bone marrow transplant Day 0 Drug: Thymoglobulin 0.5 mg/kg IV on Day -9 2 mg/kg IV on Days -8, -7 Drug: Fludarabine 30 mg/M2 IV on days -6 to -2 Drug: Cyclophosphamide 14.5 mg/kg IV on days -6, -5, 3, 4 Other Name: CTX Radiation: TBI 200 cGy on day -1 Drug: Mesna 40 mg/kg IV on days 3, 4 Drug: Tacrolimus For patients 18 years or older, tacrolimus will be given per institutional standards; may be increased or later changed to a PO BID schedule. Treatment to continue until Day 365 or longer if GVHD present Drug: Mycophenolic acid mofetil 15 mg/kg PO/IV TID beginning Other Name: MMF